<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Katharina</forename><surname>Ilm</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Experimental and Clinical Research Center</orgName>
								<orgName type="department" key="dep2">Max-Delbrück-Center for Molecular Medicine</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<addrLine>Robert-Rössle-Str.10</addrLine>
									<postCode>13125</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wolfgang</forename><surname>Kemmner</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Experimental and Clinical Research Center</orgName>
								<orgName type="department" key="dep2">Max-Delbrück-Center for Molecular Medicine</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<addrLine>Robert-Rössle-Str.10</addrLine>
									<postCode>13125</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marc</forename><surname>Osterland</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Experimental and Clinical Research Center</orgName>
								<orgName type="department" key="dep2">Max-Delbrück-Center for Molecular Medicine</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<addrLine>Robert-Rössle-Str.10</addrLine>
									<postCode>13125</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Susen</forename><surname>Burock</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Gudrun</forename><surname>Koch</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Experimental and Clinical Research Center</orgName>
								<orgName type="department" key="dep2">Max-Delbrück-Center for Molecular Medicine</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<addrLine>Robert-Rössle-Str.10</addrLine>
									<postCode>13125</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pia</forename><surname>Herrmann</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Experimental and Clinical Research Center</orgName>
								<orgName type="department" key="dep2">Max-Delbrück-Center for Molecular Medicine</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<addrLine>Robert-Rössle-Str.10</addrLine>
									<postCode>13125</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><forename type="middle">M</forename><surname>Schlag</surname></persName>
						</author>
						<author role="corresp">
							<persName><forename type="first">Ulrike</forename><surname>Stein</surname></persName>
							<email>ustein@mdc-berlin.de</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Experimental and Clinical Research Center</orgName>
								<orgName type="department" key="dep2">Max-Delbrück-Center for Molecular Medicine</orgName>
								<orgName type="institution">Charité University Medicine Berlin</orgName>
								<address>
									<addrLine>Robert-Rössle-Str.10</addrLine>
									<postCode>13125</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">German Cancer Consortium</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">71DC99A24ECF7475C3C7BF5520B76D04</idno>
					<idno type="DOI">10.1186/s12943-015-0316-2</idno>
					<note type="submission">Received: 12 September 2014 Accepted: 5 February 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:23+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>KRAS mutations</term>
					<term>MACC1</term>
					<term>Prognostic marker</term>
					<term>Colorectal cancer</term>
					<term>Metastasis-free survival</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: The metastasis-associated in colon cancer 1 (MACC1) gene has been identified as prognostic biomarker for colorectal cancer (CRC).</s><s>Here, we aimed at the refinement of risk assessment by separate and combined survival analyses of MACC1 expression with any of the markers KRAS mutated in codon 12 (KRAS G12) or codon 13 (KRAS G13), BRAF V600 mutation and MSI status in a retrospective study of 99 CRC patients with tumors UICC staged I, II and III.</s></p><p><s>Findings: We showed that only high MACC1 expression (HR: 6.09, 95% CI: 2.50-14.85,</s><s>P &lt; 0.001) and KRAS G13 mutation (HR: 5.19, 95% CI: 1.06-25.45,</s><s>P = 0.042) were independent prognostic markers for shorter metastasis-free survival (MFS).</s><s>Accordingly, Cox regression analysis revealed that patients with high MACC1 expression and KRAS G13 mutation exhibited the worst prognosis (HR: 14.48, 95% CI: 3.37-62.18,</s><s>P &lt; 0.001).</s><s>Patients were classified based on their molecular characteristics into four clusters with significant differences in MFS (P = 0.003) by using the SPSS 2-step cluster function and Kaplan-Meier survival analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion:</head><p><s>According to our results, patients with high MACC1 expression and mutated KRAS G13 exhibited the highest risk for metachronous metastases formation.</s><s>Moreover, we demonstrated that the "Traditional pathway" with an intermediate risk for metastasis formation can be further subdivided by assessing MACC1 expression into a low and high risk group with regard to MFS prognosis.</s><s>This is the first report showing that identification of CRC patients at high risk for metastasis is possible by assessing MACC1 expression in combination with KRAS G13 mutation.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>Colorectal cancer (CRC) is the third most common cancer worldwide <ref type="bibr" target="#b0">[1]</ref>.</s><s>According to the state of the art for classification, colorectal carcinoma can be divided into three major pathways based on the underlying molecular alterations <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s><s>The majority of CRC belong to the "Traditional pathway" which reflects the adenomacarcinoma sequence model <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>.</s><s>Two additional pathways where recently described, the "Serrated" and "Alternate pathway" <ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref>, which are characterized by differences in the microsatellite instability (MSI) status and mutations in the KRAS or BRAF oncogenes.</s><s>In advanced stages metastatic spread shortens the 5-year survival rate from 90% to 10% <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7]</ref>.</s><s>Risk estimation by using genetic factors for early identification of high risk patients is still limited <ref type="bibr" target="#b7">[8]</ref>.</s></p><p><s>One promising candidate is the metastasis-associated in colon cancer 1 (MACC1) gene.</s><s>MACC1 is an important prognostic marker for metastases formation in CRC <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b9">10]</ref>.</s></p><p><s>Other promising molecular markers are oncogenic KRAS mutations, which are detectable in 30-50% of CRC tumors <ref type="bibr" target="#b10">[11]</ref>.</s><s>The most frequent point mutations in codon 12 (KRAS G12) and 13 (KRAS G13) of exon 2 result in constitutive activation of KRAS and downstream pathways <ref type="bibr" target="#b11">[12]</ref>.</s><s>Although the role of KRAS mutations as predictive biomarkers for anti-EGFR-targeted therapy is well characterized, there is a need to clarify their relevance as prognostic biomarkers for recurrence of metastatic CRC <ref type="bibr" target="#b12">[13]</ref>.</s></p><p><s>In this retrospective study, we attempted to improve the prognostic value of MACC1 for CRC metastasis using separate and combined survival analyses of MACC1 expression levels and KRAS G12 or G13 mutations in tumors of CRC patients.</s><s>In addition, we investigated the prognostic significance of BRAF V600 mutation and MSI status, two of the most promising prognostic and predictive markers in the landscape of molecular biomarkers.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Associations of MACC1 expression with the KRAS G12, KRAS G13 and BRAF V600 mutations as well as MSI status</head><p><s>In total, 99 patients with patho-histologically confirmed primary colorectal adenocarcinomas with Union for International Cancer Control (UICC) stages I, II and III were included in this study.</s><s>This patient study protocol was approved by the Institutional Review Board (IRB) of the Charité Universitätsmedizin Berlin, complied with the Helsinki Declaration.</s><s>The median metastasis-free survival (MFS) time and overall survival (OS) time of the patients were 56.0 and 79.4 months, respectively.</s><s>This tumor marker study based on hypothesis-driven approaches was designed in compliance with the REMARK guidelines <ref type="bibr" target="#b13">[14]</ref>.</s><s>MACC1 mRNA expression level of the tumors were quantified using quantitative reverse transcriptase PCR <ref type="bibr" target="#b8">[9]</ref>.</s><s>All patient and tumor characteristics are shown in detail in the Additional file 1: Table <ref type="table" target="#tab_0">S1</ref>-S4.</s><s>For KRAS and BRAF mutation analyses as well as MSI status determination DNA sequencing methods were used <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b15">16]</ref>.</s><s>All used material and methods are described in detail in Additional file 2. The molecular characteristics in this cohort (Additional file 1: Table <ref type="table">S2</ref>) demonstrate the general distribution within colorectal tumors and mutual exclusivity of the oncogenes KRAS and BRAF <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b14">15]</ref>.</s></p><p><s>MACC1 expression was significantly higher in primary tumors of patients who developed metachronous metastases during the follow-up period (P = 0.009; Figure <ref type="figure">1A</ref>), which confirmed previously described coherences <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b9">10]</ref>.</s><s>We showed for the first time a correlation of high MACC1 expression with tumors harboring KRAS mutations (G12 or G13) (P = 0.049; Figure <ref type="figure">1B</ref>) <ref type="bibr" target="#b6">[7]</ref>.</s><s>Separate analyses of primary tumors harboring the KRAS G13 mutation exhibited a significantly higher MACC1 expression (P = 0.010; Figure <ref type="figure">1D</ref>), but not for KRAS G12 mutated tumors (P = 0.156; Figure <ref type="figure">1C</ref>).</s><s>High MACC1 expression also correlated with BRAF wild type (wt) (P = 0.027; Figure <ref type="figure">1E</ref>) and microsatellite stable (MSS)/MSI-Low (MSI-L) (P = 0.009; Figure <ref type="figure">1F</ref>) tumors.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Association of MACC1 expression, KRAS G12 or G13 mutation, BRAF mutation and MSI status with MFS</head><p><s>We performed Kaplan-Meier survival analyses (Figure <ref type="figure">2</ref>) and univariate Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of the tumor characteristics with MFS (Additional file 1: Table <ref type="table">S5</ref>).</s><s>Interestingly, univariate Cox regression and Log Rank test revealed that in the set of analyzed markers, only high MACC1 expression levels and KRAS G13 mutation emerged as prognostic factors for MFS.</s><s>Patients with high MACC1 expression levels (Figure <ref type="figure">2A</ref>, Log Rank P &lt; 0.001; Cox regression: low vs. high, HR: 5.02, 95% CI: 2.19-11.53,</s><s>P &lt; 0.001) or KRAS G13 mutation (Figure <ref type="figure">2D</ref>, Log Rank P = 0.022; Cox regression: wt vs. KRAS G13, HR: 4.25, 95% CI: 1.21-14.93,</s><s>P = 0.024) in their primary tumors exhibited a significantly poorer prognosis.</s><s>Although the role of KRAS G13 mutation as a predictive biomarker for anti-EGFR-targeted therapy <ref type="bibr" target="#b17">[18]</ref> is well characterized, the prognostic value of KRAS G13 mutation in patients with CRC is controversial <ref type="bibr" target="#b18">[19]</ref>.</s><s>Various reports either encourage or dismiss KRAS mutations as prognostic biomarker for disease-specific survival rates or to predict liver or lung metastases <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref>.</s><s>Data of the Kirsten Ras in Colorectal Cancer Collaborative Group Studies (RASCAL I) suggested that the risk of recurrence and death is increased by the presence of KRAS mutations <ref type="bibr" target="#b10">[11]</ref>, and the updated RASCAL II study confined the correlation of KRAS mutation and survival prognosis to the G12V mutation <ref type="bibr" target="#b24">[25]</ref>.</s><s>According to our results, comparison of mutated KRAS tumors with KRAS wt tumors had no significant impact on MFS (Figure <ref type="figure">2B</ref>, Log Rank P = 0.499; Cox regression: wt vs. KRAS G12 or G13, HR: 1.40, 95% CI: 0.63-3.09,</s><s>P = 0.409).</s><s>Studies comparing the effects of KRAS G12 with KRAS G13 mutations are rare <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b23">24]</ref>.</s><s>Therefore separate analyses of KRAS G12 and KRAS G13 mutations in the tumors were included and demonstrated that especially the KRAS G13, but not KRAS G12 (Figure <ref type="figure">2C</ref>, Log Rank P = 0.654; Cox regression: wt vs. KRAS G12, HR: 1.29, 95% CI: 0.55-3.03,</s><s>P = 0.556), mutations were prognostic for reduced MFS.</s><s>Separate analyses of the most prominent G12 mutations (G12V, G12D and G12C) revealed no significant impact of these mutations on MFS prognosis (Log Rank P = 0.826, P = 0.896 and P = 0.766; respectively).</s><s>Furthermore, BRAF V600 mutation (Figure <ref type="figure">2E</ref>, Log Rank P = 0.656; Cox regression: wt vs. BRAF V600, HR: 0.75, 95% CI: 0.18-3.17,</s><s>P = 0.694) or MSS/MSI-L (Figure <ref type="figure">2F</ref>, Log Rank P = 0.085; Cox regression: MSS/MSI-L vs. MSI-H, HR: 0.04, 95% CI: 0.00-12.05,</s><s>P = 0.272) were also not associated with worse prognosis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Combinatorial survival analyses of MACC1 expression and KRAS G12 or G13 mutation with tumor characteristics</head><p><s>Next, we analyzed the effects of clinicopathological parameters like age, gender, UICC stage, grading and postoperative treatment of the tumors concerning MFS in combination with MACC1 or KRAS mutations using multivariate Cox regression (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Only high MACC1 expression (HR: 6.09, 95% CI: 2.50-14.85,</s><s>P &lt; 0.001) and KRAS G13 mutation (HR: 5.19, 95% CI: 1.06-25.45,</s><s>P = 0.042) turned out to be independent prognostic markers for shorter MFS in the set of analyzed biomarkers.</s><s>To our knowledge, this is the first study showing a prognostic relevance of KRAS G13 for MFS in CRC patients and demonstrating KRAS G13 mutation as independent risk factor of age, gender, UICC stage, grading and postoperative treatment for metachronous metastases development.</s></p><p><s>In addition, we performed multivariate Cox regression combining MACC1 expression level with the tumor characteristics KRAS G12 or G13 mutation, BRAF V600 mutation and MSI status (Additional file 1:</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A B C D E</head><p><s>Figure <ref type="figure">1</ref> Associations of MACC1 expression with KRAS mutation, BRAF mutation or MSI status.</s><s>MACC1 mRNA expression levels of the tumors were quantified using quantitative reverse transcriptase PCR <ref type="bibr" target="#b8">[9]</ref>.</s><s>Tumor DNA was extracted and subjected to PCR for amplification of KRAS and BRAF sequences and analyzed by sequencing <ref type="bibr" target="#b14">[15]</ref>.</s><s>MSI Analysis System was used for MSI status determination as described previously <ref type="bibr" target="#b15">[16]</ref>.</s><s>Tumors were discriminated in Microsatellite stable (MSS)/MSI-low (MSI-L; 0 or 1 markers demonstrating instability) or MSI-High (MSI-H; two or more markers instable).</s><s>A Significantly increased MACC1 mRNA expression levels were detected in primary tumors of patients with metachronous metastases (P = 0.009).</s><s>B MACC1 expression level was significantly increased in KRAS mutated (G12 or G13) tumors compared to tumors with KRAS wild type (KRAS wt) (P = 0.049).</s><s>C There were no significant differences of MACC1 expression in KRAS G12 mutated compared to KRAS wt tumors (P = 0.156).</s><s>D Primary tumors harboring G13 mutated KRAS showed a significantly increased MACC1 expression level (P = 0.010).</s><s>E In BRAF wt tumors MACC1 expression was significantly increased compared to BRAF V600 mutated tumors (P = 0.027).</s><s>F MACC1 expression of MSS/MSI-L tumors was significantly increased compared to MSI-H tumors (P = 0.009).</s><s>Significance in differential mRNA expression was determined by Mann-Whitney U-test.</s><s>Calculation of q-values from the corresponding P-values was performed to control for the false discovery rate (FDR) <ref type="bibr" target="#b16">[17]</ref>.</s><s>FDR-adjusted P-values less than 0.05 were considered to be statistically significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A B C D G E F</head><p><s>Figure <ref type="figure">2</ref> Patients' metastasis-free survival prognosis according to MACC1 mRNA expression, KRAS mutation, BRAF mutation and MSI status.</s><s>The Kaplan-Meier method was used to estimate cumulative survival rates.</s><s>MFS time was defined as the time period from the date of surgery to the date of confirmed distant metastases or to the date of last follow-up contact/death for censored patients.</s><s>A Patients with high MACC1 expression exhibited a statistically significant reduced MFS (P &lt; 0.001).</s><s>B No significant differences of MFS between KRAS mutated (G12 or G13) and KRAS wt tumors (P = 0.499) were detected.</s><s>C KRAS G12 mutation showed no significant impact on MFS prognosis (P = 0.654).</s><s>D MFS of patients with KRAS G13 mutated tumors compared to patients with KRAS wt was significantly reduced (P = 0.022).</s><s>E There was no significant impact of BRAF V600 mutation on MFS prognosis (P = 0.656).</s><s>F In MSS/MSI-L tumors we observed a tendency of shorter MFS (P = 0.085) compared to MSI-H tumors, but differences were not significant.</s><s>G Tumors with high MACC1 expression and KRAS G13 exhibited the shortest MFS (mean: 19.0 months) compared to tumors with high MACC1 expression and KRAS wt (mean: 88.7 months, P = 0.039).</s><s>Significance of differences in survival rates were assessed using the Log Rank test.</s><s>P-values less than 0.05 were considered to be statistically significant.</s><s>The P-values, hazard ratios (HR) and 95% confidence intervals (CI) of different parameters concerning MFS were calculated using Cox regression analyses.</s><s>The analysis was performed separately for each factor with the parameters listed in the table being introduced as covariates, respectively.</s><s>Here, we show that MACC1 expression subdivides this cluster into a low risk (16%, light green) and high risk (45%, dark green) group.</s><s>The highest risk (60%) patients were classified in Cluster 4 representing the "Alternate pathway" (in red).</s><s>According to our results these tumors are now characterized by a high MACC1 expression and mutated KRAS G13.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A B C</head><p><s>Table <ref type="table">S5</ref>).</s><s>This analysis revealed that MACC1 was statistically significant independent for MFS prognosis of these molecular markers (HR: 4.20, 95% CI: 1.80-9.81,</s><s>P = 0.001).</s><s>Therefore, we conducted combinatorial survival prognosis of the independent prognostic markers MACC1 expression and KRAS G13 mutation.</s><s>Interestingly, patients with the worst prognosis were characterized by high MACC1 expression and KRAS G13 mutation (HR: 14.48, 95% CI: 3.37-62.18,</s><s>P &lt; 0.001).</s><s>These patients had the shortest MFS time (Figure <ref type="figure">2G</ref>, Log Rank: P = 0.039 mean: 18.99 months, 95% CI: 10.64-27.34)</s><s>compared to patients with high MACC1 expression and KRAS wt tumors (Additional file 1: Table <ref type="table">S6</ref>).</s><s>The identification of CRC patients at high risk for metastasis formation is possible by assessing MACC1 expression in combination with KRAS G13 mutations.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cluster classification</head><p><s>Using integrative 2-step cluster analysis based on the presence of the proven markers in our cohort four clusters of patients with a different risk for metastasis formation could be distinguished and coincide well with the presumed pathways (Figure <ref type="figure" target="#fig_0">3</ref>).</s><s>According to CRC classification by <ref type="bibr">Leggett</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>This exploratory study has limitations especially due to the limited number of patient samples.</s><s>But this cohort has also several strengths: The marker analyses were performed with microdissected cryosections verified by an experienced pathologist.</s><s>Furthermore the studied cohort is very well characterized and only samples from preoperatively untreated patients with very long follow-up data and complete clinicopathological information were used.</s></p><p><s>In conclusion, our results underline the high relevance of MACC1 and KRAS G13 mutation for CRC metastasis prognosis.</s><s>This is the first study showing a prognostic relevance of KRAS G13 for MFS in CRC patients.</s><s>Furthermore, high MACC1 expression and KRAS G13 mutation are independent prognostic markers for metachronous metastases development.</s><s>Accordingly, combinatorial survival prognosis revealed that patients with high MACC1 expression and KRAS G13 mutation exhibited the worst prognosis.</s></p><p><s>Interestingly, the conventional CRC classification can be extended and refined by inclusion of MACC1 expression and mutated KRAS G13 as independent markers.</s><s>Therefore, this refinement allows improved individualized prognosis and intervention strategies for the majority of CRC patients in clinical routine.</s></p><p><s>and PH assisted with performance of mutation and expression analyses.</s><s>US and PMS designed the study, provided clinical advice and revised the manuscript for important intellectual content.</s><s>All authors critically analyzed, read and approved the final manuscript.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 3</head><label>3</label><figDesc><div><p><s>Figure 3 Classification of CRC patients with regard to their molecular characterization.</s><s>A Integrative 2-step cluster analyses allowed the differentiation of four clusters with regard to their tumor characteristics.</s><s>Clustering of the tumors concerning KRAS G13 mutation, MACC1 expression, BRAF V600 mutation and MSI status was performed by the SPSS 2-step cluster function.</s><s>The order of the molecular markers represents the significance of the predictor was determined by the 2-step cluster analysis function.</s><s>†MSS: includes MSS/MSI-L samples.</s><s>B Kaplan-Meier survival analysis revealed significantly different survival times for the four clusters (P = 0.003).</s><s>Patients of Cluster 1 had the best prognosis and patients in Cluster 4 had the worst prognosis.</s><s>C According to Leggett and Whitehall [2] Cluster 1 (in blue) represents the "Serrated pathway" which is characterized by the lowest risk (10%) for metastasis formation.</s><s>Cluster 2 and Cluster 3 belong to the "Traditional pathway" (in green) with intermediate risk for metastasis formation.Here, we show that MACC1 expression subdivides this cluster into a low risk (16%, light green) and high risk (45%, dark green) group.</s><s>The highest risk (60%) patients were classified in Cluster 4 representing the "Alternate pathway" (in red).</s><s>According to our results these tumors are now characterized by a high MACC1 expression and mutated KRAS G13.</s></p></div></figDesc><graphic coords="5,142.57,494.84,218.44,129.76" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Impact of clinicopathological parameters in combination with MACC1 and KRAS mutation status concerning MFS</s></p></div></figDesc><table><row><cell>Covariates</cell><cell cols="2">Multivariate</cell><cell cols="2">Multivariate mutated</cell><cell cols="2">Multivariate G13</cell><cell>Multivariate G12</cell></row><row><cell></cell><cell>MACC1</cell><cell></cell><cell cols="2">(G12 or G13) KRAS</cell><cell cols="2">mutated KRAS</cell><cell>mutated KRAS</cell></row><row><cell></cell><cell cols="2">P-value HR (95% CI)</cell><cell cols="2">P-value HR (95% CI)</cell><cell cols="2">P-value HR (95% CI)</cell><cell>P-value HR (95% CI)</cell></row><row><cell>Molecular Markers MACC1 (low vs. high)</cell><cell cols="3">&lt;0.001 6.09 (2.50-14.85) 0.302</cell><cell cols="2">1.55 (0.67-3.59) 0.042</cell><cell>5.19 (1.06-25.45) 0.543</cell><cell>1.34 (0.52-3.42)</cell></row><row><cell>KRAS G12/G13 (wt vs. mutated)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age at diagnosis (&lt;60) vs. (&gt;60) years</cell><cell>0.970</cell><cell cols="2">1.02 (0.41-2.52) 0.892</cell><cell cols="2">0.94 (0.39-2.26) 0.648</cell><cell>1.30 (0.43-3.93) 0.940</cell><cell>1.04 (0.37-2.90)</cell></row><row><cell>By gender Male vs. Female</cell><cell>0.890</cell><cell cols="2">0.94 (0.41-2.17) 0.969</cell><cell cols="2">1.02 (0.44-2.34) 0.494</cell><cell>1.42 (0.52-3.91) 0.963</cell><cell>0.98 (0.41-2.35)</cell></row><row><cell>UICC stage (I) vs. (II + III)</cell><cell>0.473</cell><cell cols="2">1.65 (0.42-6.53) 0.191</cell><cell cols="2">2.42 (0.64-9.09) 0.356</cell><cell>2.16 (0.42-11.10) 0.115</cell><cell>3.59 (0.73-17.54)</cell></row><row><cell>By grading (G1 + 2) vs. (G3 + 4)</cell><cell>0.416</cell><cell cols="2">0.64 (0.22-1.88) 0.257</cell><cell cols="2">0.53 (0.18-1.59) 0.305</cell><cell>0.45 (0.10-2.06) 0.094</cell><cell>0.28 (0.06-1.24)</cell></row><row><cell>By postoperative treatment Untreated</cell><cell>0.064</cell><cell cols="2">2.37 (0.95-5.93) 0.447</cell><cell cols="2">1.40 (0.59-3.29) 0.723</cell><cell>1.22 (0.41-3.57) 0.483</cell><cell>1.39 (0.55-3.49)</cell></row><row><cell>vs. treated</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>This work was supported by the German Cancer Consortium (DKTK) (to US).</s><s>We would like to thank Susann Förster and Christoph Treese for sharing their experience in biostatistics.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consent</head><p><s>Written informed consent was obtained from the patient for the publication of this report and any accompanying images.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional files</head><p><s>Additional file 1: Supplementary Tables.</s><s>Table <ref type="table">S1</ref>.</s><s>Patient characteristics with regard to MACC1 expression and the determined relative risk (RR) with corresponding 95% confidence intervals (CI) are shown.</s><s>Table <ref type="table">S2</ref>.</s><s>The frequencies of mutations and MSI status of the tumors and corresponding MACC1 expression are shown.</s><s>Table <ref type="table">S3</ref>.</s><s>Contains the localization of the metachronous, distant metastases of the patients within the cohort.</s><s>Table <ref type="table">S4</ref>.</s><s>The frequencies of postoperative treatment within the patient cohort are shown.</s><s>Table <ref type="table">S5</ref>.</s><s>Includes the univariate and multivariate Cox regression analyses of the analyzed biomarkers.</s><s>The analysis was performed separately for each factor with the parameters listed in the table being introduced as covariates, respectively.</s><s>Table <ref type="table">S6</ref>.</s><s>Includes the MFS time and P-values for the analyzed biomarkers were calculated using the Kaplan-Meier survival analyses and the Log Rank test.</s></p><p><s>Additional file 2: Materials and methods.</s><s>This file includes detailed information regarding tumor specimens, RNA and DNA isolation, mutations analysis, MSI status determination and statistical analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p><s>The authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.</s></p><p><s>Authors' contributions KI and WK contributed equally as first authors.</s><s>They performed the analysis, interpreted the results and wrote the manuscript.</s><s>MO and SB assisted with the statistical analysis and provided critical analysis of the manuscript.</s><s>GK</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">I</forename><surname>Soerjomataram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dikshit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Eser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mathers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rebelo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="E359" to="E386" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Role of the serrated pathway in colorectal cancer pathogenesis</title>
		<author>
			<persName><forename type="first">B</forename><surname>Leggett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Whitehall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastroenterology</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="2088" to="2100" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Molecular origins of cancer: Molecular basis of colorectal cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Markowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Bertagnolli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope unit="page" from="2449" to="2460" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Colorectal carcinogenesis: road maps to cancer</title>
		<author>
			<persName><forename type="first">D-L</forename><surname>Worthley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V-L</forename><surname>Whitehall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K-J</forename><surname>Spring</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B-A</forename><surname>Leggett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="3784" to="3791" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">A genetic model for colorectal tumorigenesis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Fearon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vogelstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="759" to="767" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Monzon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ogino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Meh</forename><surname>Hammond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Halling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Bloom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Nikiforova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Pathol Lab Med</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="1600" to="1606" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Integrative marker analysis allows risk assessment for metastasis in stage II colon cancer</title>
		<author>
			<persName><forename type="first">U</forename><surname>Nitsche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Balmert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Schuster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Slotta-Huspenina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Herrmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg</title>
		<imprint>
			<biblScope unit="volume">256</biblScope>
			<biblScope unit="page" from="763" to="771" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>discussion 771</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy</title>
		<author>
			<persName><forename type="first">V</forename><surname>Deschoolmeester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Specenier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lardon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Vermorken</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="699" to="731" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis</title>
		<author>
			<persName><forename type="first">U</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Walther</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Arlt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Schwabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Fichtner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="59" to="67" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">MACC1 -a novel target for solid cancers</title>
		<author>
			<persName><forename type="first">U</forename><surname>Stein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Ther Targets</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1039" to="1052" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Kirsten ras mutations in patients with colorectal cancer: the multicenter &quot;RASCAL&quot; study</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Andreyev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Norman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Oates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Clarke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="675" to="684" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">EGFR and KRAS in colorectal cancer</title>
		<author>
			<persName><forename type="first">B</forename><surname>Markman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Javier</forename><surname>Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Capdevila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tabernero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv Clin Chem</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="71" to="119" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Clinical relevance of KRAS mutations in codon 13: Where are we?</title>
		<author>
			<persName><forename type="first">T-K</forename><surname>Er</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C-C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bujanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Herreros-Villanueva</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">REporting recommendations for tumor MARKer prognostic studies (REMARK)</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Mcshane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Taube</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Clark</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Clin Pract Oncol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="416" to="422" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Pleau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Greenspan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Stevens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">V</forename><surname>Rajan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="3551" to="3554" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Development of a fluorescent multiplex assay for detection of MSI-High tumors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Bacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Flanagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Smalley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Nassif</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Burgart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Halberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dis Markers</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="237" to="250" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Statistical significance for genomewide studies</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Storey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tibshirani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci U S A</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="9440" to="9445" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab</title>
		<author>
			<persName><forename type="first">S</forename><surname>Tejpar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Celik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schlichting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Sartorius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bokemeyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Cutsem</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="3570" to="3577" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yokota</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Agents Med Chem</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="163" to="171" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tejpar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Delorenzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fiocca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Klingbiel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="466" to="474" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Association of K-ras mutations with liver metastases from colorectal carcinoma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Tsunoda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Iijima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tsunoda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nakao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Miyaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kusano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anticancer Res</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="2471" to="2476" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer</title>
		<author>
			<persName><forename type="first">M-J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kwon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-O</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">347</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">K-ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mannan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Hahn-Strömberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">APMIS</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="459" to="468" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Influence of KRAS mutation status in metachronous and synchronous metastatic colorectal adenocarcinoma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Serna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Weatherby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Abdel-Misih</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="6243" to="6252" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Kirsten ras mutations in patients with colorectal cancer: the &quot;RASCAL II&quot; study</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Andreyev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Norman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Oates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Dix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Iacopetta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="692" to="696" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
